(firstQuint)Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN in Subjects With Primary Immunodeficiency.

 This is an open-label, single-arm, historically controlled, prospective, multicenter phase III study to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN cent in subjects with primary immunodeficiency diseases.

 Subject will be infused every 21 to 28 days according to their previous IVIG treatment schedule.

 Subjects treated every 28 days will receive 13 study IVIG infusions.

 Subject treated every 21 days will receive 17 study IVIG infusions.

 Duration of treatment:The total duration of treatment is 12 months.

.

 Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN in Subjects With Primary Immunodeficiency@highlight

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN cent in subjects with primary immunodeficiency diseases.

